PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04556617 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped study terminated due to business realignment

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: PLX2853 20 mg
DRUG: Olaparib
DRUG: Abiraterone acetate
DRUG: Prednisone
DRUG: PLX2853 40 mg
DRUG: PLX2853 80 mg

Sponsor

Opna Bio LLC